Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Forest Laboratories buys Gruenenthal’s cystic fibrosis business

Forest Laboratories buys Gruenenthal’s cystic fibrosis business

21st December 2010

Forest Laboratories has agreed a deal to purchase fellow pharmaceutical company Gruenenthal's cystic fibrosis business in Europe.

The transaction will see Forest acquire all rights to the antibiotic treatment colistin, as well as the colistin-based dry powder inhaler Colobreathe, which had previously been licensed to Forest.

This deal will allow Forest to expand its presence in the European cystic fibrosis market, while Gruenenthal will be able to place greater focus on its core pain medication business operations.

Howard Solomon, chairman and chief executive officer of Forest, expressed confidence that Colobreathe will benefit patients once it is approved by European healthcare regulators.

"We are pleased to have reached this agreement with Gruenenthal on the heels of the recently announced collaboration between our two companies in the area of pain," he added.

The earlier partnership, which was confirmed earlier this month, will see Forest and Gruenenthal work together on developing the novel oral small molecule analgesic GRT 6005.ADNFCR-8000103-ID-800303480-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.